Human medicines European public assessment report (EPAR): Relistor, methylnaltrexone bromide, Date of authorisation: 01/07/2008, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Atazanavir Viatris (previously Atazanavir Mylan), atazanavir, Date of authorisation: 22/08/2016, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Uzpruvo, ustekinumab, Date of authorisation: 05/01/2024, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Givlaari, givosiran, Date of authorisation: 02/03/2020, Revision: 8, Status: Authorised

Sponsor guidance: New safety module on the annual safety report

Enpr-EMA priority activities

18th Industry Standing Group (ISG) meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 21 September 2026, 09:00 (CEST) to 21 September 2026, 12:30 (CEST)

Human medicines European public assessment report (EPAR): Susvimo, ranibizumab, Date of authorisation: 18/09/2026, Status: Authorised

Human medicines European public assessment report (EPAR): Pregabalin Viatris Pharma (previously Pregabalin Pfizer), pregabalin, Date of authorisation: 10/04/2014, Revision: 39, Status: Authorised

Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 18, Status: Authorised